Welcome to our dedicated page for Danaher Corporation SEC filings (Ticker: DHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Danaher’s 10-K can exceed 250 pages, weaving life-sciences revenue, diagnostics margins, and dozens of recent acquisitions into dense footnotes. Finding how Cytiva lifted bioprocessing sales or when executives exercise options is time-consuming. Stock Titan decodes every Danaher SEC filing, turning complexity into clarity.
Our platform delivers AI-powered summaries that make Danaher SEC filings explained simply. Need the latest Danaher quarterly earnings report 10-Q filing? We tag segment performance so you can compare consumables growth quarter-over-quarter. Tracking governance? Get Danaher proxy statement executive compensation highlights in plain English. Material event on a new acquisition? See the Danaher 8-K material events explained the moment it posts to EDGAR. And because insider activity moves the stock, our alerts surface Danaher insider trading Form 4 transactions—including Danaher Form 4 insider transactions real-time—before the market digests them.
Investors use these insights to:
- Monitor R&D intensity versus peers with Danaher annual report 10-K simplified
- Spot integration costs from recent M&A using Danaher earnings report filing analysis
- Review Danaher executive stock transactions Form 4 ahead of earnings calls
- Understand environmental disclosures and DBS efficiency metrics without reading every footnote
Whether you’re understanding Danaher SEC documents with AI for strategic research or scanning for trading catalysts, Stock Titan provides real-time updates, expert context, and the confidence to act on every disclosure.
Danaher (DHR): Director A. Shane Sanders reported the acquisition of 186.308 phantom shares on 10/31/2025 on a Form 4. The award was made under the Non-Employee Directors Deferred Compensation Plan, which converts deferred director fees (and dividend accruals) into notional shares based on the NYSE closing price on the quarterly date. The filing notes a reference closing price of $215.38.
Following this transaction, Sanders beneficially owned 2,536.686 derivative securities (phantom shares), held directly. Phantom shares convert into Danaher common stock on a one-for-one basis upon distribution, and the reporting person is fully vested in all amounts deferred under the plan.
Danaher (DHR) reported a routine insider transaction: director Linda Filler acquired 13.208 phantom shares on 10/31/2025 under the company’s Non‑Employee Directors Deferred Compensation Plan. These notional units track Danaher common stock and are valued using the NYSE closing price of $215.38 on the transaction date.
The phantom shares convert into Danaher common stock on a one‑for‑one basis upon distribution, and the reporting person is fully vested under the plan. Following the transaction, Filler beneficially owned 8,903.266 derivative securities, reported as directly owned.
Danaher Corporation (DHR) reported an insider equity compensation update. Director Teri List acquired 11.322 phantom shares on 10/31/2025 under the Non-Employee Directors Deferred Compensation Plan, which converts deferred cash fees into notional Danaher common stock equivalents based on the closing price on the transaction date.
The filing lists a reference price of $215.38 per share, reflecting the NYSE closing price used for the quarter’s deferral calculation. Phantom shares convert into Danaher common stock on a one-for-one basis upon distribution, and the reporting person is fully vested in amounts deferred under the plan. Following this transaction, Ms. List beneficially owned 7,631.994 derivative (phantom) shares, held directly.
Danaher (DHR) — Rule 144 notice of proposed sale. A holder filed to sell 600,000 shares of Danaher common stock through Monness, Crespi, Hardt & Co., Inc., with an aggregate market value of $128,406,000. The approximate sale date is 10/31/2025 on the NYSE.
The filing lists 706,349,563 shares outstanding. The seller originally acquired 1,900,000 shares on 06/11/2021 via a distribution from Capital Yield Corporation in connection with the liquidation of a closely held corporation.
Danaher Corporation reported Q3 results with sales of $6,053 million, up from $5,798 million a year ago. Operating profit rose to $1,154 million and net earnings increased to $908 million, delivering diluted EPS of $1.27 versus $1.12.
Year-to-date, sales reached $17,730 million and net earnings were $2,417 million. The effective tax rate was 15.6% for the quarter. By segment in Q3, Biotechnology generated $1,798 million of sales, Life Sciences $1,792 million, and Diagnostics $2,463 million. The company recorded $101 million of impairments in the quarter, primarily in Biotechnology and Diagnostics.
Cash from operating activities was $4,299 million for the nine-month period. Danaher repurchased $3,088 million of common stock year-to-date and repaid $500 million of notes on September 15, 2025. After quarter-end, it issued CHF 1,250 million of Swiss franc bonds for general corporate purposes. Shares outstanding were 706,349,563 as of October 16, 2025.
Danaher Corporation furnished an 8‑K announcing its third‑quarter results. On October 21, 2025, the company issued a press release for the quarter ended September 26, 2025, attached as Exhibit 99.1 and incorporated by reference. The information is furnished under Item 2.02 and is expressly stated as not deemed “filed” under Section 18 of the Exchange Act.
Jonathan Leiken, identified as SVP - General Counsel of Danaher Corporation (DHR), submitted an initial Form 3 reporting the event dated 08/25/2025. The filing states that no securities are beneficially owned by Mr. Leiken (listed as 0 shares) and includes an exhibit referencing a Power of Attorney (Exhibit 24). The form was signed on behalf of Mr. Leiken by an attorney‑in‑fact, James F. O'Reilly, on 08/27/2025. This is an initial insider disclosure with no reported direct or derivative holdings.
Teri List, a director of Danaher Corporation (DHR), reported a sale of 2,778 shares of Danaher common stock on 08/22/2025 at a reported price of $211.058 per share. After the sale, the reporting person beneficially owned 20,750.672 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Danaher Corporation (DHR) Form 144 notice reports a proposed sale of 2,778 shares of common stock through Fidelity Brokerage Services LLC on 08/22/2025 on the NYSE with an aggregate market value of $586,319.96. The shares were acquired by stock option exercise from the issuer on 07/02/2025 and were paid for in cash on that date. The filing lists the total number of shares outstanding as 716,051,590. The form indicates no securities sold during the past three months for the account and includes the statutory representation that the seller has no undisclosed material adverse information.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
